We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
No 2p placing!!!
That`s what is required. Here`s hoping.
Peter
Are you listening and understand how thus is panning out now
You bought in too early
Best hope for this is if a big boy takes it over . It cannot do this own it’s own
I bought but says sell.
4p placing or less?
Short lived rise. Positive RNS but feel the comment regarding further funding req are stopping this rising. One to hold as they are expanding their products greatly.
Currentg sp
Come on guys get behind your share there's alot going for this company
Good rns this morning the unknown buy at 8am is mine
Medical Oncologist, Professor Frances Boyle AM, Director of the Patricia Ritchie Centre for Cancer Care and Research at Mater Hospital and Professor of Medical Oncology at the University of Sydney, said: "We are very pleased to be the first hospital in Australia to have the Steriwave nasal decolonization system. The pathogens patients carry have long been known to cause hospital-acquired infections, especially for the weak and immunocompromised. Having a rapid non-antibiotic approach to decolonizing the nose – a major source of infection transmission
Mater Hospital, North Sydney has become the first Australian hospital to use Ondine Biomedical's award-winning light-activated antimicrobial technology Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Mater Hospital, North Sydney, a private hospital in New South Wales, has become the first Australian hospital to start using its light-activated antimicrobial Steriwave® technology to prevent the spread of hospital-acquired infections (HAIs). Mater Hospital, located in North Sydney and founded in 1906, is part of St. Vincent's Health Australia Group, Australia's largest not-for-profit provider of health and aged care services.
Medical Oncologist, Professor Frances Boyle AM, Director of the Patricia Ritchie Centre for Cancer Care and Research at Mater Hospital and Professor of Medical Oncology at the University of Sydney, said: "We are very pleased to be the first hospital in Australia to have the Steriwave nasal decolonization system. The pathogens patients carry have long been known to cause hospital-acquired infections, especially for the weak and immunocompromised. Having a rapid non-antibiotic approach to decolonizing the nose – a major source of infection transmission – is a benefit to our patients." Orthopaedic Spine Surgeon Dr John Street, Director of the Integrated Ambulatory Spine Program at Vancouver Coastal Health and upcoming President of the Canadian Spine Society, was a keynote speaker at the recent 2024 Spine Society of Australia 35th Annual Scientific Meeting
Re-rating is justified. Am thinking of 20p initially.
Expect results to be substantial - but realistic
Yes - As usual we remain totally under the radar, but this will not always be the case.
We are now in Australia, so that is something new, and gradually Steriwave will gain recognition throughout the World.
As we await the 2023 results, I was reminded of an item in the 2022 results:
"Financial Highlights
· Revenues of $0.6 million (2021: $2.6 million). The decrease was anticipated and primarily due to the loss of pandemic-related sales to the meat processing plants as vaccinations became available."
If the contract with meat processing plants was worth say $2m, the potential revenues that could be generated from the range of opportunities that are now being developed must be significant. Even if the 2023 results disappoint some people, I am optimistic about the longer term outlook.
Currently
Not long to wait for results now
Ondine Biomedical Inc on Monday announced that Steriwave has been used for the first time in an Australian hospital.
The Vancouver-based life sciences company said that Mater Hospital in North Sydney has become the first Australian hospital to start using Steriwave for the prevention of hospital-acquired infections.
Medical Oncologist Frances Boyle said: "We are very pleased to be the first hospital in Australia to have the Steriwave nasal decolonization system. The pathogens patients carry have long been known to cause hospital-acquired infections, especially for the weak and immunocompromised. Having a rapid non-antibiotic approach to decolonizing the nose - a major source of infection transmission - is a benefit to our patients."
Steriwave is a light-activated antimicrobial which employs patented nasal photodisinfection technology to eliminate bacteria, fungi and viruses located on human tissues.
According to Ondine, surgical site infections are "one of the most significant complications in cardiac surgery patients and are strongly associated with poorer prognosis".
This comes after Ondine announced earlier this month that Steriwave had been approved by HCA Healthcare UK for use in its healthcare facilities.
Not much reaction to more good news. Taken a small buy Today even though no revenue details have been given again. Will have to wait for results. Well under the radar is this one.
Is that the results will be out in the beginning of May.
They will show the increase in commercializing during 2023,
and show more movement towards profit.
The impression I get is that great strides have been made,
and will show how undervalued the SP has been, and show
that a re-rating is justified. Am thinking of 20p initially.
Also expect a larger company may move to take-over.
imho- dyor
One can imagine the impact on revenue of Ondine as Steriwave gains recognition in hospitals throughout the world which adopt it as the preferred method to achieve huge reductions in fatalities
The resultant share price achievement, which is currently tiny, would be significant
Thank you for your note, Peter. We recognize that there are questions and are working to address this issue.
Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=obi.L
Tempting price, but can see even lower until they confirm income levels and orders in RNS
6.53-6.8p current low price
Entry into ICU market expands revenue potential
Following interest from Canadian Hospitals, Ondine prepares to enter the Intensive Care Unit (ICU) market
· Treatment of patients in ICUs would significantly expand Ondine's
potential market opportunity.
· Hundreds of thousands of patients are admitted to the ICU every year
in Canada alone, with an average stay of over four days.